11/4/2026

speaker
Conference Operator
Operator

Greetings. Welcome to the Mineralis Therapeutics Third Quarter 2026 conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry. of LifeSite Advisors. Please go ahead, sir.

speaker
Dan Ferry
LifeSci Advisors

Thank you. I would like to welcome everyone joining us today for our third quarter 2026 conference call. This afternoon, after the close of market trading, we issued a press release providing our third quarter 2026 financial results and business updates. A replay of today's call will be available on the investor section of our website approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-K and subsequent filings. Please note that these forward-looking statements reflect our opinions only as of today, November 4, 2026. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. I would now like to turn the call over to Jon Congleton, Chief Executive Officer of Mineralis Therapeutics.

speaker
Jon Congleton
Chief Executive Officer

Thank you, Dan. Good afternoon, everyone, and welcome to our third quarter 2026 financial results and corporate update conference call. We've had an exciting and productive quarter, and I look forward to sharing our updates. Today, I'm joined by Adam Levy, our chief financial officer, and Eric Warren, our chief commercial officer. I'll begin with an overview of the business and our recent clinical progress. Eric will then provide a commercial update. and Adam will review our third quarter financial results before we open the call for your questions. We are now just weeks away from our PDUFA target date of December 22nd. While the FDA continues its review of the NDA, our focus is on completing our launch preparations so that we are ready to reach patients soon after the potential approval of Larunderstat. Approximately 20 million adults with hypertension treated with two or more drugs fail to achieve their blood pressure goal. The implications are clear. If people with hypertension can achieve their blood pressure goals, they are less likely to have poor outcomes that impact their quality of life and longevity. Providing innovations to help people achieve their blood pressure goals is what drives our work every day. A critical part of that work is the publication and presentation of La Runderstadt data for the medical community to build awareness, understanding, and enthusiasm for its clinical profile. The major medical meetings this fall are giving us a series of opportunities to present data on the Runderstep that highlight its differentiated profile. We recently presented new data at the AHA Hypertension Scientific Sessions and at ASN Kidney Week. And we have an important late-breaking presentation coming this Sunday at the American Heart Association Scientific Sessions. We believe the data we have presented to date Add to the strength of the data from our clinical program and suggest the potential of lorundrastat to help patients with difficult-to-treat hypertension reach their guideline-recommended systolic blood pressure goals. These data include a new analysis of our pivotal Phase III LAUNCH-HTN trial. Participants in LAUNCH-HTN had uncontrolled or treatment-resistant hypertension despite being treated with two to five antihypertensive therapies. In this 12-week analysis, 46% of participants treated with lorandrostat 50 milligrams achieved the AHA-ACC guideline-recommended office systolic blood pressure target of less than 130 millimeters of mercury, and more than two-thirds achieved a systolic blood pressure reduction of at least 10 millimeters of mercury. We believe these are compelling data in a population that had previously not been able to reach their goal with existing therapies. We also presented the final results from our Phase 2 Explore OSA trial in overweight or obese adults with moderate to severe obstructive sleep apnea and hypertension. As many as 70% to 80% of adults with resistant hypertension have OSA. Their nighttime blood pressure is often elevated and is considered a significant driver of cardiovascular risk. In Explore OSA, lorundrastat 50 milligrams, taken once daily in the evening, reduced morning systolic blood pressure by 11.1 millimeters of mercury at week four, compared with a 1.0 millimeter mercury reduction with placebo. Although we did not observe a measurable change in the apnea hypopnea index, The blood pressure reduction was consistent with what we saw in our pivotal trials, and the safety and tolerability profile was favorable, with no evidence of serious safety events, including hyperkalemia. We believe these results further emphasize the potential of Lurunderset in a high-risk subpopulation in whom blood pressure is particularly difficult to control. New long-term efficacy and safety data from our ongoing Transform HTN Open Label Extension Trial will be featured in a late-breaking scientific presentation at the American Heart Association Scientific Sessions 2026 on November 8th in Chicago. Durable blood pressure control and a well-characterized long-term safety profile are important considerations for physicians managing a chronic condition like hypertension. We look forward to sharing these data with the medical community. As we have discussed, aldosterone plays a central role in hypertension, as well as other cardiorenal and metabolic disorders. We remain committed to advancing our work in aldosterone-driven disease states and are evaluating the next steps in the clinical development of lorandrostat. Once we have finalized those plans, we will share them with you. We're also excited to have two new board members join Mineralis as we prepare for the launch of La Runderstad. Chris Peterson and Lonel Coates are two experienced executives that bring a wealth of commercial expertise to Mineralis at this juncture of our corporate life. They will be providing their insights, perspective, and experience to our management team as we prepare the market, the asset, and the company for commercialization. As a part of this transition, Derek Duraco, who joined the board while we were a private company, will be concluding his tenure at the end of this year. I want to thank Derek for his support and guidance over the past several years during our development stage. With that, I'll turn the call over to Eric to provide a commercial update.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API